Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
about
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsCytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresisSelective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease.Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be?Innovative therapeutics for inflammatory bowel diseaseRegulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.Leukocytapheresis for the treatment of IBD.Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.Colorectal cancer chemoprevention by 2 beta-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid.Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy.Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis.Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy?Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis.The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.
P2860
Q26768280-8763205D-1755-4E23-8834-1F95A5C112FBQ33855532-C05F0EBE-31B4-45C6-BA64-BC3C9252DC74Q34008773-A991276D-FC8D-4F76-B56C-A82D83E171F8Q34831143-442BB8A8-4C96-40A2-BF0E-6EE9164D4AD0Q36210314-031AC692-BDD7-4A6F-997B-586FCBBDC226Q36522931-BE2F69D2-B15B-4535-A3EA-EE797415CAF4Q36802524-AC4E7C1E-27F9-4EF5-8876-F96574218BBAQ37220846-7DAD30F8-E1AE-4921-8B3F-FA1BD1A9D46FQ37229788-59AD15E3-CD5F-4BC7-96C5-53FEE84D685FQ39255696-B1AF8FD4-861C-4999-B67E-D62AC24846A7Q42458633-841FD930-B310-4D3A-8945-16B5A63B536AQ42625889-5B834FC4-11DB-4461-868C-62EE35A0642BQ45067486-6166D342-9968-466E-8C92-12C460A528EDQ46821578-FD779B49-B462-4646-BC1E-3DB5B6EBE9C5Q47130594-59B2AF0E-76FB-4EDF-942D-64C946C71F3EQ47694487-88C40549-E47B-4BEC-A9E2-36D24C757707Q48071894-3B58D827-A628-4D20-98DD-D07CF459AF78Q51765029-A3EB7A2A-8195-45AE-BF83-C74F1142F261
P2860
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@en
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@nl
type
label
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@en
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@nl
prefLabel
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@en
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@nl
P2860
P356
P1476
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.
@en
P2093
Hiroyuki Hanai
P2860
P304
P356
10.3748/WJG.V12.I47.7568
P407
P577
2006-12-01T00:00:00Z